In a significant stride for medical innovation, NeuroBell, a medtech startup focused on improving neonatal care, has partnered with the Parkview Mirro Center for Research and Innovation to advance its groundbreaking seizure detection technology. The partnership began in 2022 and centers on a pioneering device designed to detect seizures in newborns quickly and efficiently.
Leslie Adair, an innovation project specialist at the Mirro Center, outlined the partnership and its goals. The collaboration provided NeuroBell with access to vital clinical environments and expertise necessary to refine and evaluate their neonatal brain monitor under real-world conditions. The project’s ultimate aim is to detect abnormalities earlier in vulnerable infants, improving outcomes through timely intervention.
Traditional neonatal seizure detection often relies on electroencephalography (EEG) equipment, which can be complex, cumbersome, and requires interpretation by specialized professionals. NeuroBell’s device seeks to simplify this process by delivering accurate, real-time monitoring that can be operated in broader clinical settings, expanding access to essential diagnostic capabilities.
By working with the Mirro Center, NeuroBell has been able to engage with clinicians to receive feedback and make iterative improvements to their technology. The collaboration also supports broader healthcare innovation by enabling startups to partner with established healthcare systems to validate and implement new medical technologies.
This initiative is part of Parkview’s ongoing efforts to support medical entrepreneurship and apply cutting-edge tools to advance patient care. As the device moves further along the path to clinical adoption, it represents a promising contribution to neonatal medicine and an example of successful cross-sector collaboration in healthcare innovation.
Source: https:// – Courtesy of the original publisher.
